logo

For the Inventor, By the Inventor

Tokyo, Japan

Masanobu Kawakami

This inventor holds 5 USPTO granted patents. Top assignees: The Rockefeller University, Eddio Corporation, Other. Active years: 1986-2002.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masanobu Kawakami. Retrieved from https://idiyas.com/inventor/masanobu-kawakami

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 5

Forward Citations = 273(Granted Patents)


Location History:

  • Tokyo, JP (1986 - 2001)
  • Tokyo 113, JP (2002)

Company Filing History:

goldMedal3 out of 751 
 
The Rockefeller University
 patents
silverMedal1 out of 5 
 
Eddio Corporation
 patents
bronzeMedal1 out of 834,513 
Other
 patents

Years Active: 1986-2002

Loading Chart...
5 patents (USPTO):Explore Patents
1. 6419927 - Method for reducing adverse effects of a human 70kDa mediator which results from endotoxin stimulation of macrophages (2002-07-16),
2. 6309640 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock assay) (2001-10-30),
3. 5130652 - AC magnetic flux leakage flaw detecting apparatus for detecting flaws in (1992-07-14),
4. 4822776 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock (1989-04-18),
5. 4603106 - Lipoprotein lipase suppression by endotoxin-induced mediator (shock (1986-07-29),

Title: Masanobu Kawakami: Innovator in Therapeutic Antibodies

Introduction

Masanobu Kawakami is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of therapeutic antibodies, particularly in relation to macrophage stimulation and endotoxin effects. With a total of 5 patents, his work has garnered attention in the scientific community.

Latest Patents

Kawakami's latest patents include innovative methods aimed at reducing the adverse effects of a human 70kDa mediator resulting from endotoxin stimulation of macrophages. One of his patents details therapeutic uses of antibodies capable of neutralizing the adverse effects in humans of the approximately 70 kDa mediator produced upon invasive stimulation of macrophages by contact with endotoxin. Another significant patent focuses on lipoprotein lipase suppression by endotoxin-induced mediators, providing pharmaceutical compositions that comprise neutralizing antibodies to the 70 kDa mediator produced under similar conditions.

Career Highlights

Throughout his career, Kawakami has worked with prestigious institutions, including The Rockefeller University. His research has been pivotal in advancing the understanding of macrophage behavior and the development of therapeutic interventions.

Collaborations

Kawakami has collaborated with esteemed colleagues such as Anthony Cerami and Akio Kokubu, contributing to a rich exchange of ideas and innovations in the field.

Conclusion

Masanobu Kawakami's work in therapeutic antibodies and macrophage stimulation represents a significant advancement in medical science. His innovative patents and collaborations highlight his dedication to improving human health through research and invention.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…